Bli medlem
Bli medlem

Du är här


Outlook for financial year 2016: aap aims for more than 20% trauma sales growth

aap Implantate AG / Outlook for financial year 2016: aap aims for more than
20% trauma sales growth. Processed and transmitted by NASDAQ OMX Corporate
Solutions. The issuer is solely responsible for the content of this
* Sales forecast for FY/2016 between EUR 30 million and EUR 34 million
* Sales organisation expanded and stronger focus on established markets
* Dynamic sales development expected from second half of the year
* Cost reduction planned in all divisions except sales

Implantate AG (XETRA: AAQ.DE) aims to return to the growth track in financial
year 2016. In this context in particular the trauma business shall serve as
the growth driver. The Management Board anticipates trauma sales growth of
20% to 25% this year. The company's growth strategy is focused especially on
established markets as the U.S., the DACH (Germany, Austria, Switzerland)
region and other European countries. At the same time sales development in
the BRICS and SMIT countries shall be stabilised.

In response to the business development in recent quartersaap
significantly expanded its sales organisation. The sales team was strengthened with several executives with extensive experience and proven track records in the industry based on many years of service with renowned international medical technology companies.
Thanks to the substantial extension of the LOQTEQ® portfolio in financial year 2015aap
can now provide with an indication coverage of more than 90% for the treatment of big bone fractures. As a result the product family's attractiveness further increases, both for established markets and for hospital and purchasing groups as well as tendering procedures.
Based on the measures initiated and against the background of current global market developments the Management Board expects sales of EUR 30 million to EUR 34 million and an EBITDA of EUR 0.0 million to EUR 1.0 million for financial year 2016.
For the first quarter of 2016 the Management Board anticipates sales of EUR 4.5 million to EUR 6.0 million and an EBITDA of EUR -2.0 million to EUR -1.0 million. The background of this forecast is on the one hand a quarterly fluctuation in the biomaterials business primarily due to the ordering behaviour of the major customers for bone cements and mixing systems. On the other hand the Management Board expects that the sales measures initiated in the trauma business will become effective from the second half of 2016 and should then be reflected in a perceptibly more dynamic sales development. In this regard, it should be mentioned that the development of sales and earnings figures should be evaluated as an overall economic review on an annual basis rather than on a quarterly basis.
Management Agenda 2016

's Management Board has specified its targets for the current financial year as Management Agenda in four strategic and operational action areas.
Management Agenda Targets for 2016

| Accelerating value-based innovations |
| Completion of LOQTEQ® portfolio with a focus on polyaxial fixation technology |
|as well as foot and ankle |
| CE mark for the antibacterial silver coating technology |
| |
| Maintenance of a freshness index of at least 20% |

| Enhancing market access |
| Substantial sales contribution from the US business |
| Establishment of DACH region and further European countries as core markets |
| Stabilisation of sales development in BRICS and SMIT states |

| Optimising operational efficiency |
| Cost reduction in all divisions except sales |
| Increase of sales efficiency |
| Optimisation of working capital management |

| Focus on trauma |
| Conclude divestment ofaap |
|Biomaterials GmbH (bone cements and mixing systems as well as biomaterials) |
| Sale of the remaining interest of 33% inaap |
|Joints GmbH |
| |
|(Contract manufacturing for joint implants) |

A key element of the corporate strategy is the development of innovative and IP protected technologies and products, which build the basis for continuous value creation.aap
's patented antibacterial silver coating technology addresses on the one hand a problem in surgery which hasn't yet been resolved adequately (infection risk when using metal implants) and has on the other hand a high value creation potential due to its wide range of applications. The superior target the Management Board continues to pursue within its strategy is to transformaap
into a focused trauma company.

In the course of its future financial communicationaap
will report on sales developments in the trauma business (LOQTEQ®, standard trauma and trauma complementary biomaterials) and the biomaterials business (Bone cements and corresponding accessories as well as biomaterials).
plans to publish its consolidated annual financial report 2015 on 30 March

Implantate AG

Implantate AG is a globally operating medical device company headquartered in
Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides
the innovative anatomical plating system LOQTEQ® a wide range of cannulated
screws as well as standard plates and screws. In the biomaterials business
the company is specialized on bone cements and mixing systems. In
German-speaking countriesaap
Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors
in more than 60 countries at the international level. In the biomaterials
business sales are handled via OEM and private label cooperations with
several selected international orthopedic and trauma companies.aap
Implantate AG's stock is listed in the Prime Standard segment of Frankfurt
Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's
App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements ofaap
to be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or

For inquiries please contact:aap
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin,

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail:


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.